- Home
- EU vs PHAR Comparison
EU vs PHAR Comparison
Compare EU & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EU
- PHAR
- Stock Information
- Founded
- EU 2009
- PHAR 1988
- Country
- EU United States
- PHAR Netherlands
- Employees
- EU N/A
- PHAR N/A
- Industry
- EU Other Metals and Minerals
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- EU Basic Materials
- PHAR Health Care
- Exchange
- EU Nasdaq
- PHAR Nasdaq
- Market Cap
- EU 669.1M
- PHAR 618.3M
- IPO Year
- EU N/A
- PHAR N/A
- Fundamental
- Price
- EU $3.18
- PHAR $8.42
- Analyst Decision
- EU Strong Buy
- PHAR Strong Buy
- Analyst Count
- EU 2
- PHAR 3
- Target Price
- EU $6.50
- PHAR $27.00
- AVG Volume (30 Days)
- EU 1.5M
- PHAR 5.6K
- Earning Date
- EU 03-27-2025
- PHAR 03-13-2025
- Dividend Yield
- EU N/A
- PHAR N/A
- EPS Growth
- EU N/A
- PHAR N/A
- EPS
- EU N/A
- PHAR N/A
- Revenue
- EU $44,972,063.00
- PHAR $285,745,000.00
- Revenue This Year
- EU N/A
- PHAR $20.08
- Revenue Next Year
- EU $55.73
- PHAR $9.22
- P/E Ratio
- EU N/A
- PHAR N/A
- Revenue Growth
- EU N/A
- PHAR 30.64
- 52 Week Low
- EU $3.02
- PHAR $6.65
- 52 Week High
- EU $5.05
- PHAR $13.20
- Technical
- Relative Strength Index (RSI)
- EU 40.93
- PHAR 40.05
- Support Level
- EU $3.17
- PHAR $7.95
- Resistance Level
- EU $3.57
- PHAR $9.35
- Average True Range (ATR)
- EU 0.18
- PHAR 0.52
- MACD
- EU -0.02
- PHAR -0.16
- Stochastic Oscillator
- EU 7.32
- PHAR 22.76
About EU enCore Energy Corp.
enCore Energy Corp together with its subsidiary, is engaged in the acquisition and exploration of resource properties. The holds a portfolio of uranium assets located in New Mexico, South Dakota, Wyoming, Texas, Utah, Colorado, and Arizona in the USA, and is advancing its properties with a focus on utilizing in-situ recovery. The company's material properties and projects are the Rosita Project located in Texas, the Alta Mesa Uranium project in Texas, the Crownpoint and Hosta Butte Uranium Project located in New Mexico, the Dewey Burdock Project located in South Dakota, and the Gas Hills Project located in Wyoming.
About PHAR Pharming Group N.V.
Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.